Merck's Tulisokibart Nails Key Goal in Mid-Stage Skin Disease Study

Merck has announced positive results from a mid-stage study of its experimental skin disease drug, tulisokibart. The treatment aims to alleviate symptoms of hidradenitis suppurativa, a chronic condition causing painful lumps, abscesses, and scarring. According to the company's statement, 72% of patients who received the highest dose of tulisokibart achieved at least a 50% reduction in inflammatory skin lesions after 16 weeks. This compares favorably with just 35% of those on placebo.

The study also measured the effect of tulisokibart on more severe cases, finding that up to 41% of patients on the drug achieved a 75% reduction in lesions. In contrast, only 15% of those on placebo reached this milestone.

Merck notes that safety was comparable between treatment and placebo groups, indicating no significant adverse effects from tulisokibart.